Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.

Gynecologic oncology - 1 Mar 2022

Xia Yue Yin, Gronwald Jacek, Karlan Beth, Lubinski Jan, McCuaig Jeanna M, Brooks Jennifer, Moller Pal, Eisen Andrea, Sun Sophie, Senter Leigha, Bordeleau Louise, Neuhausen Susan L, Singer Christian F, Tung Nadine, Foulkes William D, Sun Ping, Narod Steven A, Kotsopoulos Joanne

Abstract excerpt

Background BRCA1 and BRCA2 (BRCA) mutation carriers face a high lifetime risk of developing ovarian cancer. Oral contraceptives are protective in this population; however, the impact of other types of contraception (e.g. intrauterine devices, implants, injections) is unknown. We undertook a matched case-control study to evaluate the relationship between type of contraception and risk of ovarian cancer among women...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Carcinoma, Ovarian Epithelial

Share to Case-Control Studies

Share to Contraceptives, Oral

Share to Heterozygote

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 35063280
DOI: 10.1016/j.ygyno.2022.01.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.PMID 35063280Read ↗

Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.Semantic proximity Read ↗

Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.Semantic proximity Read ↗

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.Semantic proximity Read ↗

Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.Semantic proximity Read ↗

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.Semantic proximity Read ↗

Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies.Semantic proximity Read ↗

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.Semantic proximity Read ↗

Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.Semantic proximity Read ↗

Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2.Semantic proximity Read ↗

Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.Semantic proximity Read ↗

Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.